Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Dechra Pharmaceuticals PLC Director's Dealing 2018

Oct 24, 2018

4797_dirs_2018-10-24_a43c0d6e-8a32-45a8-aed8-b8b75c53569b.html

Director's Dealing

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 0805F

Dechra Pharmaceuticals PLC

24 October 2018

24 October 2018

Dechra® Pharmaceuticals PLC

(Dechra or the Company)

Notification and public disclosure of transactions by

persons discharging managerial responsibilities (PDMRs)

Dechra Pharmaceuticals PLC announces that on 22 October 2018, the following PDMRs exercised nil cost options over ordinary shares of 1p each in the Company. The options were granted to them on 15 September 2015 pursuant to the Dechra Pharmaceuticals PLC Long Term Incentive Plan (the LTIP). The exercise of the options was subject to the achievement of performance conditions which were satisfied in full so that the options vested at 100%. The PDMRs sold sufficient shares (acquired pursuant to the exercise) in order to fund the resulting tax liability.

Name Capacity Options Exercised Shares Sold Sale Price per share Total beneficial shareholding following this announcement Percentage of issued share capital
Ian Page Director 90,721 42,768 £21.395965 786,650 0.767%
Tony Griffin Director 22,641 11,355 £21.395965 75,606 0.074%

The Notification of Dealing Forms set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.

Notification of Dealing Form

1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a) Name Ian Page
2. Reason for the notification
a) Position/status Director/PDMR
b) Initial notification/

amendment
Initial Notification
3. Details of the Issuer
a) Name Dechra Pharmaceuticals PLC
b) LEI code 213800J4UVB5OWG8VX82
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument

Identification code
Ordinary Shares of 1 pence each

ISIN: GB0009633180
b) Nature of the transaction Exercise of 90,721 options under the Company's Long Term Incentive Plan
c) Price(s) and volumes(s) Price(s)

£Nil Cost
Volume(s)

90,721
d) Aggregated information

-   Aggregate volume

-   Price
N/A
e) Date of the transaction 2018.10.22
f) Place of the transaction Outside a trading venue
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a) Name Ian Page
2. Reason for the notification
a) Position/status Director/PDMR
b) Initial notification/

amendment
Initial Notification
3. Details of the Issuer
a) Name Dechra Pharmaceuticals PLC
b) LEI code 213800J4UVB5OWG8VX82
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument

Identification code
Ordinary Shares of 1 pence each

ISIN: GB0009633180
b) Nature of the transaction Partial sale of shares obtained under the Company's Long Term Incentive Plan to satisfy tax liability
c) Price(s) and volumes(s) Price(s)

£21.395965
Volume(s)

42,768
d) Aggregated information

-   Aggregate volume

-   Price
42,768

£915,062.63
e) Date of the transaction 2018.10.23
f) Place of the transaction London Stock Exchange
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a) Name Tony Griffin
2. Reason for the notification
a) Position/status Director/PDMR
b) Initial notification/

amendment
Initial Notification
3. Details of the Issuer
a) Name Dechra Pharmaceuticals PLC
b) LEI code 213800J4UVB5OWG8VX82
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument

Identification code
Ordinary Shares of 1 pence each

ISIN: GB0009633180
b) Nature of the transaction Exercise of 22,641 options under the Company's Long Term Incentive Plan
c) Price(s) and volumes(s) Price(s)

£nil
Volume(s)

22,641
d) Aggregated information

-   Aggregate volume

-   Price
N/A
e) Date of the transaction 2018.10.22
f) Place of the transaction Outside a trading venue
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a) Name Tony Griffin
2. Reason for the notification
a) Position/status Director/PDMR
b) Initial notification/

amendment
Initial Notification
3. Details of the Issuer
a) Name Dechra Pharmaceuticals PLC
b) LEI code 213800J4UVB5OWG8VX82
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument

Identification code
Ordinary Shares of 1 pence each

ISIN: GB0009633180
b) Nature of the transaction Partial sale of shares obtained under the Company's Long Term Incentive Plan to satisfy tax liability.
c) Price(s) and volumes(s) Price(s)

£21.395965
Volume(s)

11,355
d) Aggregated information

-   Aggregate volume

-   Price
11,355

£242,951.18
e) Date of the transaction 2018.10.23
f) Place of the transaction London Stock Exchange

For further information, please contact:

Melanie Hall, Company Secretary                         

Telephone number: 01606 814730

About Dechra

Dechra is an international specialist veterinary pharmaceuticals and related products business.  Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.  For more information please visit: www.dechra.com

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

DSHFKQDDQBDDPKB